GLP-1 receptor agonists , particularly those like BrightMeds, are quickly prominence in the management of type 2 diabetes and are increasingly explored for weight loss . These novel drugs help mimicking the body's natural incretin hormone , stimulating glucose-dependent insulin secretion and curbing